Literature DB >> 7829078

Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.

K A Quane1, K E Keating, J M Healy, B M Manning, R Krivosic-Horber, I Krivosic, N Monnier, J Lunardi, T V McCarthy.   

Abstract

The ryanodine receptor gene (RYR1) has been shown to be mutated in a small number of malignant hyperthermia (MH) pedigrees. Missense mutations in this gene have also been identified in two families with central core disease (CCD), a rare myopathy closely associated with MH. In an effort to identify other RYR1 mutations responsible for MH and CCD, we used a SSCP approach to screen the RYR1 gene for mutations in a family exhibiting susceptibility to MH (MHS) where some of the MHS individuals display core regions in their muscle. Sequence analysis of a unique aberrant SSCP has allowed us to identify a point mutation cosegregating with MHS in the described family. The mutation changes a conserved tyrosine residue at position 522 to a serine residue. This mutation is positioned relatively close to five of the six MHS/CCD mutations known to date and provides further evidence that MHS/CCD mutations may cluster in the amino terminal region of the RYR1 protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829078     DOI: 10.1006/geno.1994.1483

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  19 in total

1.  Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

Authors:  K E Keating; L Giblin; P J Lynch; K A Quane; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

2.  Oxidative capacity and fatigability in run-trained malignant hyperthermia-susceptible mice.

Authors:  Clement Rouviere; Benjamin T Corona; Christopher P Ingalls
Journal:  Muscle Nerve       Date:  2012-04       Impact factor: 3.217

3.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Regulation of Ryanodine Receptor Ion Channels Through Posttranslational Modifications.

Authors:  Gerhard Meissner
Journal:  Curr Top Membr       Date:  2010       Impact factor: 3.049

Review 5.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

6.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.

Authors:  V Barone; O Massa; E Intravaia; A Bracco; A Di Martino; V Tegazzin; S Cozzolino; V Sorrentino
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

7.  Calcitonin gene-related peptide restores disrupted excitation-contraction coupling in myotubes expressing central core disease mutations in RyR1.

Authors:  Ana Victoria Vega; Roberto Ramos-Mondragón; Aida Calderón-Rivera; Angel Zarain-Herzberg; Guillermo Avila
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

8.  Characterization and temporal development of cores in a mouse model of malignant hyperthermia.

Authors:  Simona Boncompagni; Ann E Rossi; Massimo Micaroni; Susan L Hamilton; Robert T Dirksen; Clara Franzini-Armstrong; Feliciano Protasi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

Authors:  J M Healy; K A Quane; K E Keating; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

10.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.